EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Zacks
More News
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.
Zacks
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Zacks
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
Zacks
Reasons Why Investors Should Consider Betting on Neurocrine Stock
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Zacks
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
Zacks
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
Zacks
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.
Zacks
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
Zacks
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira gains a reimbursement boost as UnitedHealthcare separately covers Exparel in outpatient care, expanding access to non-opioid postsurgical pain treatment.